Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Coave Therapeutics
ChromaDex Rides Nestle Deal To 14% Q4 Growth; Mannatech, USANA End Year In Slumps
ChromaDex reports Niagen ingredient sales growth propelled by upfront minimum purchase from Nestlé Health Science; and Mannatech and USANA both reported larger full-year sales dips after ending 2022 in slumps.
Tech Transfer Roundup: Tiba And CEPI Strategize Together On ‘Disease X’
Immix collaborates with Israeli research institutions on BCMA-targeted CAR-T therapy. NeoImmuneTech/NIAID alliance could pave way for “animal rule” approval in acute radiation syndrome.
USANA Looks Inside US, Outside Nutrition Sector For Growth Drivers, Acquiring Oolah, Rise Bar
USANA also signals its turning outside nutritional products sector for potential growth driver. One of two firms it’s acquiring, Oola Life Inc., also provides life coach services directly to customers as well as nutritional supplements.
US Q3 Health And Wellness Results: Chromadex, Lannett, Mannatech And USANA
ChromaDex trims loss, adds Nestle as Niagen customer; currency exchange slams Mannatech; Asia-Pacific sales, currency exchange Rock USANA results; and Lannett sees upsides after 25% sales slide.
- Drug Delivery
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- HORAMA S.A.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.